Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC is poised for a significant leap in the biopharmaceutical field with the promising trajectory of U.S. patent grants for its novel Aminoindane new chemical entities, aimed at treating mental health disorders such as PTSD. This development, backed by Graft Polymer’s investment in and collaboration with Awakn Life Sciences, is expected to address the considerable unmet needs in mental health and addiction treatment. The company’s CEO, Anthony Tennyson, expressed enthusiasm for Awakn’s ongoing progress and the impact of their joint efforts.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
